1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41PMID:
20591140.
2. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016;2:16057PMID:
27510637.
3. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-3733. PMID:
9360532.
4. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899. PMID:
10372683.
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
6. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83. PMID:
14742691.
7. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002;143:1076-1084. PMID:
11861535.
8. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891-4899. PMID:
11606457.
9. Lee JR, Kim SH. Anti-Mullerian hormone and female reproduction. Korean J Obstet Gynecol 2009;52:285-300.
10. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602-1618. PMID:
30052961.
11. Bhattacharya SM, Jha A, DasMukhopadhyay L. Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome. Int J Gynaecol Obstet 2016;132:210-213. PMID:
26613823.
12. Chung JP, Yiu AK, Chung TK, Chan SS. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol 2014;27:166-171. PMID:
24656700.
13. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82:139-146. PMID:
20654754.
14. Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008;103:44-49. PMID:
18635183.
15. Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod 2011;26:214-220. PMID:
21098626.
16. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924-1931. PMID:
18579512.
17. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-514. PMID:
14714587.
18. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957-5962. PMID:
14671196.
19. Mes-Krowinkel MG, Louwers YV, Mulders AG, de Jong FH, Fauser BC, Laven JS. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril 2014;101:1757-1965.e1. PMID:
24680368.
21. Plouvier P, Peigné M, Gronier H, Robin G, Catteau-Jonard S, Dewailly D. Is the suppressive effect of cyproterone acetate on serum anti-Müllerian-hormone levels in women with polycystic ovary syndrome stronger than under oral contraceptive pill? Gynecol Endocrinol 2016;32:612-616. PMID:
26890873.
22. Fábregues F, Castelo-Branco C, Carmona F, Guimerá M, Casamitjana R, Balasch J. The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. Gynecol Endocrinol 2011;27:216-224. PMID:
20500102.
23. Dursun F, Güven A, Yıldız M. Assessment of anti-Müllerian hormone level in management of adolescents with polycystic ovary syndrome. J Clin Res Pediatr Endocrinol 2016;8:55-60. PMID:
26761944.
24. Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol 2011;27:587-592. PMID:
20836726.
25. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007;134:196-201. PMID:
17335955.
26. Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency
in vivo
. Endocrinology 1991;128:509-517. PMID:
1702704.
27. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236. PMID:
15788499.
28. Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med 2014;41:86-91. PMID:
25045633.
29. Chun S. 1-h Postprandial glucose level is related to the serum anti-Müllerian hormone level in women with polycystic ovary syndrome. Gynecol Endocrinol 2015;31:815-818. PMID:
26291804.
30. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 2009;32:281-286. PMID:
19017778.
31. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009;24:2917-2923. PMID:
19617605.
32. Skałba P, Cygal A, Madej P, Dąbkowska-Huć A, Sikora J, Martirosian G, et al. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2011;158:254-259. PMID:
21752527.
33. Park CH, Chun S. Association between serum gonadotropin level and insulin resistance-related parameters in Korean women with polycystic ovary syndrome. Obstet Gynecol Sci 2016;59:498-505. PMID:
27896252.
34. Shim AR, Hwang IY, Lim KJ, Choi YM, Jeon YE, Seo SK, et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: the relationship with clinical, hormonal and metabolic characteristics. Korean J Obstet Gynecol 2011;54:659-665.
35. Caglar GS, Kahyaoglu I, Pabuccu R, Demirtas S, Seker R. Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet 2013;288:905-910. PMID:
23553200.
36. Cassar S, Teede HJ, Moran LJ, Joham AE, Harrison CL, Strauss BJ, et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol (Oxf) 2014;81:899-906. PMID:
25040369.
37. Monash University. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Melbourne: Monash University; 2018.